Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DN2OL8
|
|||
| Drug Name |
Amlitelimab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Atopic dermatitis [ICD-11: EA80; ICD-10: L20] | Phase 2 | [2] | ||
| Company |
Sanofi Bridgewater, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TAX transcriptionally-activated glycoprotein 1 (OX40) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| TSLP Signaling Pathway | ||||
| Reactome | TNFs bind their physiological receptors | |||
| WikiPathways | Vitamin D Receptor Pathway | |||
| TSLP Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05421598) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma. U.S.National Institutes of Health. | |||
| REF 2 | OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753. | |||
| REF 3 | OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics. 2022 Dec 8;14(12):2753. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.